| Literature DB >> 34569626 |
Muriël Reudink1, Charlotte J L Molenaar1, Cynthia S Bonhof2,3, Loes Janssen1, Floortje Mols2,3, Gerrit D Slooter1.
Abstract
BACKGROUND AND OBJECTIVES: Surgery for colorectal cancer (CRC) negatively affects health-related quality of life (HRQoL). Addressing shortcomings in literature, the purpose of this study was to evaluate the impact of surgery for CRC on the course of HRQoL from baseline up to 2 years after diagnosis.Entities:
Keywords: PROFILES; colorectal cancer; colorectal resection; health-related quality of life; recovery; surgery
Mesh:
Year: 2021 PMID: 34569626 PMCID: PMC9292688 DOI: 10.1002/jso.26685
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 2.885
Figure 1Flowchart of the study
Baseline demographic and clinical characteristics of all patients that underwent colonic or rectal resection for colorectal cancer (n = 415)
| Variable | All respondents ( | Right‐sided resection ( | Left‐sided resection ( | Rectal resection ( |
|
|---|---|---|---|---|---|
| Age at baseline (years) |
| ||||
| ≤70 | 248 (59.8%) | 76 (51.4%) | 86 (58.5%) | 86 (71.7%) | |
| >70 | 167 (40.2%) | 72 (48.6%) | 61 (41.5%) | 34 (28.3%) | |
| Gender (male) | 249 (60.0%) | 85 (57.4%) | 89 (60.5%) | 75 (62.5%) | 0.692 |
| Time between diagnosis and baseline (days) | 21 [15–28] | 21 [15–27] | 19 [13–26] | 24 [18–35] |
|
| Highest level of education | 0.344 | ||||
| Low | 41(9.9%) | 12 (8.1%) | 18 (12.2%) | 11 (9.2%) | |
| Medium | 265 (63.9%) | 89 (60.1%) | 99 (67.3%) | 77 (64.2%) | |
| High | 105 (25.3%) | 44 (29.7%) | 30 (20.4%) | 31 (25.8%) | |
| Missing | 4 (1%) | 3 (2.0%) | 0 (0%) | 1 (0.8%) | |
| BMI (kg/m2) | 0.362 | ||||
| <25 | 147 (35.4%) | 53 (35.8%) | 47 (32.0%) | 47 (39.2%) | |
| 25−30 | 161 (38.8%) | 57 (38.5%) | 55 (37.4%) | 49 (40.8%) | |
| ≥30 | 102 (24.6%) | 35 (23.6%) | 44 (29.9%) | 23 (19.2%) | |
| Missing | 5 (1.2%) | 3 (2.0%) | 1 (0.7%) | 1 (0.8%) | |
| ASA grade | 0.055 | ||||
| I–II | 354 (85.3%) | 119 (80.4%) | 131 (89.1%) | 104 (86.7%) | |
| III–V | 58 (14%) | 29 (19.6%) | 16 (10.9%) | 13 (10.8%) | |
| Missing | 3 (0.7%) | 0 (0%) | 0 (0%) | 3 (2.5%) | |
| Smoking | 0.542 | ||||
| Current smoker | 45 (10.8%) | 18 (12.2%) | 12 (8.2%) | 15 (12.5%) | |
| Former smoker | 241 (58.1%) | 83 (56.1%) | 84 (57.1%) | 74 (61.7%) | |
| Non‐smoker | 118 (28.4%) | 43 (29.1%) | 46 (31.3%) | 29 (24.2%) | |
| Missing | 11 (2.7%) | 4 (2.7%) | 5 (3.4%) | 2 (1.7%) | |
| Number of comorbid conditions |
| ||||
| 0 | 116 (28%) | 29 (19.6%) | 50 (34.0%) | 37 (30.8%) | |
| 1 | 135 (32.5%) | 46 (31.1%) | 46 (31.3%) | 43 (35.8%) | |
| ≥2 | 162 (39%) | 73 (49.3%) | 50 (34.0%) | 39 (32.5%) | |
| Missing | 2 (0.5%) | 0 (0%) | 1 (0.7%) | 1 (0.8%) | |
| Tumor stage (pTNM) |
| ||||
| I | 126 (30.4%) | 48 (32.4%) | 47 (32.0%) | 31 (25.8%) | |
| II | 115 (27.7%) | 51 (34.5%) | 42 (28.6%) | 22 (18.3%) | |
| III | 157 (37.8%) | 44 (29.7%) | 53 (36.1%) | 60 (50.0%) | |
| IV | 10 (2.4%) | 1 (0.7%) | 4 (2.7%) | 5 (4.2%) | |
| Unknown | 7 (1.7%) | 4 (2.7%) | 1 (0.7%) | 2 (1.7%) | |
| (Neo)adjuvant therapy (yes) | 150 (36.1%) | 35 (23.6%) | 48 (32.7%) | 67 (55.8%) |
|
| Radiotherapy only | 29 (7.0%) | 0 (0%) | 0 (0%) | 29 (24.2%) | |
| Chemotherapy only | 88 (21.2%) | 33 (22.3%) | 48 (32.7%) | 7 (5.8%) | |
| Chemo and radiotherapy | 33 (8.0%) | 2 (1.4%) | 0 (0%) | 31 (25.8%) | |
| Surgical approach |
| ||||
| Laparoscopy | 381 (91.8%) | 139 (93.9%) | 142 (96.6%) | 100 (83.3%) | |
| Open | 25 (6.0%) | 8 (5.4%) | 5 (3.4%) | 12 (10.0%) | |
| TaTME | 4 (1.0%) | 0 (0%) | 0 (0%) | 4 (3.3%) | |
| Missing | 5 (1.2%) | 1 (0.7%) | 0 (0%) | 4 (3.4%) | |
| Stoma (yes) | 73 (17.6%) | 1 (0.7%) | 3 (2.1%) | 69 (57.5%) |
|
| Diverting | 47 (11.3%) | 0 (0%) | 1 (0.7%) | 46 (38.3%) | |
| End | 25 (6.0%) | 1 (0.7%) | 2 (1.4%) | 22 (18.3%) | |
| Unknown | 1 (0.2%) | 0 (0%) | 0 (0%) | 1 (0.8% | |
| Length of hospital stay | 0.090 | ||||
| <10 days | 357 (86.0%) | 134 (90.5%) | 127 (86.4%) | 96 (80.0%) | |
| ≥10 days | 39 (9.4%) | 11 (7.4%) | 11 (7.5%) | 17 (14.2%) | |
| Missing | 19 (4.6%) | 3 (2.0%) | 9 (6.1%) | 7 (5.8%) |
Note: Values are in numbers (percentages) or median [IQR].
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; kg, kilograms; m, meters; pTNM, pathological tumor node and metastasis stage; TaTME, transanal total mesorectal excision.
Level of education: low (no or primary school); medium (lower general secondary education or vocational training); high (pre‐university education, high vocational training, university).
Figure 2Health‐related quality of life function scores over time measured with the European Organization for Research and Treatment of Cancer QLQ‐C30 questionnaire for subgroups (right‐sided resection, left‐sided resection, and rectal resection). A higher score means better functioning/global health status. For a more visually suitable display of the results, the scale ranges from 50 to 100. The actual scale ranges from 0 to 100. Between‐group analyses: *significant difference between patients that underwent right‐sided and left‐sided resection. **significant difference between patients that underwent right‐sided and rectal resection. ***significant difference between patients that underwent left‐sided and rectal resection.Within‐group analyses: asignificant difference baseline, 4‐week follow‐up; bsignificant difference baseline, 1‐year follow‐up, csignificant difference baseline, 2‐year follow‐up; dsignificant difference 4‐week, 1‐year follow‐up; esignificant difference 4‐week, 2‐year follow‐up. Analyses were adjusted for: age, time between diagnosis and baseline, number of comorbid conditions, tumor stage, (neo)adjuvant therapy, surgical approach, and stoma
Figure 3Health‐related quality of life of single items and scales over time measured with the European Organization for Research and Treatment of Cancer QLQ‐C30 questionnaire for subgroups (right‐sided resection, left‐sided resection, and rectal resection). A lower score means less symptoms. For a more visually suitable display of the results, the scale ranges from 0 to 40. The actual scale ranges from 0 to 100. Between‐group analyses: *significant difference between patients that underwent right‐sided and left‐sided resection. **significant difference between patients that underwent right‐sided and rectal resection. ***significant difference between patients that underwent left‐sided and rectal resection. Within‐group analyses: asignificant difference baseline, 4‐week follow‐up; bsignificant difference baseline, 1‐year follow‐up; csignificant difference baseline, 2‐year follow‐up; dsignificant difference 4‐week, 1‐year follow‐up; esignificant difference 4‐week, 2‐year follow‐up. Analyses were adjusted for: age, time between diagnosis and baseline, number of comorbid conditions, tumor stage, (neo)adjuvant therapy, surgical approach, and stoma